Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference, page-71

If Neu pay a dividend of $1 multiply by 80 = $80 share price.

This is the multiple that CSL and COH have applied to their dividend give or take.

I believe these company’s are what NEU can be compared with. Dividend paying global growth companies in Biotech/medical field.

Is NEU there today. NO.

FDA approval on March 12 2023 and YES they are there.

As discussed prior. $200m in annual revenue for NEU from Global sales of Trofinetide alone.

With 4 Phase 2’s in progress in 4 different areas with an even better technology. With 5 times bigger market share than Tofinetide for each indication.

If all goes well. IF.

That will be $4.2 Billion in revenue to NEU ( Utopia )

Take off the tax 30%? Operating and R&D funing $10%

Divide by 126,000,000 shares.

= Dividend

Multiply your estimated dividend multiple(depending on growth prospects at the time) to the Dividend = Share Price


This is my method. It is agricultural. Loose but lands me in a ball park for my purposes. Using comparable(soon to be) companies CSL and COH as a reference. And several other posters here arrive along similar numbers a different way.


Personally, I am going with 0.75c divi on a divi multiple of 50. So around $38 as my target. And this is just Trof in the next 18-24 months.
But, I beleive that has room to go 80+ as a multiplier. And the divi could be bigger too. So $80 to $100 Share price is not out of the question. Just for TROF.
.